Kaisa Health Group(00876.HK): Hydromorphone Hydrochloride Injection of Qinghai Pharmaceutical Obtains Drug Registration Certificate

NewTimeSpace · 2026/07/28 07:43 · By Xuran Lin

NewTimeSpace News: Kaisa Health announced on 27 July that Hydromorphone Hydrochloride Injection (specification: 1ml:2mg) produced by Qinghai Pharmaceutical, a subsidiary of the Group, has been granted a Drug Registration Certificate issued by the National Medical Products Administration (NMPA), with approval for domestic production registration.

NewTimeSpace News: On 27 July 2026, Kaisa Health Group(00876.HK) issued an announcement. Hydromorphone Hydrochloride Injection (specification: 1ml:2mg) of Qinghai Pharmaceutical Co., Limited, a subsidiary under the Group, obtained the Drug Registration Certificate issued by the NMPA on 21 July 2026, and has been approved for domestic production registration.

According to the announcement, this product is indicated for moderate to severe cancer pain, acute postoperative pain and severe pain relief. It has been included in the Catalogue of Medicinal Narcotic Drugs (2025 Edition) and is an essential therapeutic medicine for Grade II and above hospitals.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

Kaisa Health Group 00876.HK